The BBV152 vaccine, produced by Bharat Biotech International, was a whole-virion -propiolactone-inactivated SARS-CoV-2 vaccine formulated by Algel-alum or Algel-IMDG adjuvants.
Patients who are older and have systolic, diastolic, and renal dysfunction may benefit from peri-interventional preload reduction therapy before implantation of larger left atrial devices.
A 12-week treatment with empagliflozin was associated with reductions in extracellular volume, estimated plasma volume, and GFR in patients with HFrEF.
Patients with HFrEF who were diabetic or prediabetic had reduced left ventricular volumes following therapy with empagliflozin.
Ring-like nonischemic left ventricular scarring in patients with idiopathic nonsustained ventricular arrhythmias may be associated with malignant arrhythmic events.
Patients hospitalized with COVID-19 who have a history of heart failure were found to have greater mortality risk.
A novel vs reference DAPT regimen after staged PCI was found to reduce the risk for bleeding in patients with acute coronary syndrome.
Worsening renal function may be associated with left ventricular ejection fraction in patients with acute heart failure.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.
